share_log

Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) Largest Shareholders Are Individual Investors Who Were Rewarded as Market Cap Surged US$58m Last Week

Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) Largest Shareholders Are Individual Investors Who Were Rewarded as Market Cap Surged US$58m Last Week

Corbus 製藥控股有限公司”s(納斯達克股票代碼:CRBP)的最大股東是個人投資者,上週市值飆升5800萬美元,他們獲得了回報
Simply Wall St ·  05/10 06:15

Key Insights

關鍵見解

  • Significant control over Corbus Pharmaceuticals Holdings by individual investors implies that the general public has more power to influence management and governance-related decisions
  • The top 8 shareholders own 51% of the company
  • Institutional ownership in Corbus Pharmaceuticals Holdings is 26%
  • 個人投資者對Corbus Pharmicals Holdings的嚴格控制意味着公衆擁有更大的影響管理和治理相關決策的權力
  • 前8名股東擁有公司51%的股份
  • 科布斯製藥控股公司的機構所有權爲26%

If you want to know who really controls Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), then you'll have to look at the makeup of its share registry. We can see that individual investors own the lion's share in the company with 39% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

如果你想知道誰真正控制着Corbus Pharmicals Holdings, Inc.(納斯達克股票代碼:CRBP),那麼你必須看看其股票登記處的構成。我們可以看到,個人投資者擁有公司的大部分股份,所有權爲39%。換句話說,該集團將從對公司的投資中獲得最多(或損失最大)。

Clearly, individual investors benefitted the most after the company's market cap rose by US$58m last week.

顯然,在上週該公司的市值上漲了5800萬美元之後,個人投資者受益最大。

In the chart below, we zoom in on the different ownership groups of Corbus Pharmaceuticals Holdings.

在下圖中,我們放大了Corbus Pharmicals Holdings的不同所有權群體。

ownership-breakdown
NasdaqCM:CRBP Ownership Breakdown May 10th 2024
納斯達克公司:CRBP 所有權明細 2024 年 5 月 10 日

What Does The Institutional Ownership Tell Us About Corbus Pharmaceuticals Holdings?

關於Corbus Pharmicals Holdings,機構所有權告訴我們什麼?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

許多機構根據近似於當地市場的指數來衡量自己的表現。因此,他們通常會更多地關注主要指數中包含的公司。

We can see that Corbus Pharmaceuticals Holdings does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Corbus Pharmaceuticals Holdings' historic earnings and revenue below, but keep in mind there's always more to the story.

我們可以看到,Corbus Pharmicals Holdings確實有機構投資者;他們持有該公司很大一部分股票。這表明專業投資者有一定的信譽。但是我們不能僅僅依靠這個事實,因爲機構有時會像所有人一樣進行不良投資。當多家機構擁有一隻股票時,總是存在處於 “擁擠交易” 的風險。當這樣的交易出錯時,多方可能會競相快速出售股票。對於沒有增長曆史的公司,這種風險更高。你可以在下面看到Corbus Pharmicals Holdings的歷史收益和收入,但請記住,故事總是有更多內容。

earnings-and-revenue-growth
NasdaqCM:CRBP Earnings and Revenue Growth May 10th 2024
納斯達克股票代碼:CRBP 收益和收入增長 2024 年 5 月 10 日

It looks like hedge funds own 32% of Corbus Pharmaceuticals Holdings shares. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. The company's largest shareholder is Cormorant Asset Management, LP, with ownership of 19%. With 7.6% and 5.2% of the shares outstanding respectively, Adage Capital Management, L.P. and Millennium Management LLC are the second and third largest shareholders.

看來對沖基金擁有Corbus Pharmicals Holdings32%的股份。這值得注意,因爲對沖基金通常是非常活躍的投資者,他們可能會試圖影響管理層。許多人希望在短期或中期內看到價值創造(以及更高的股價)。該公司的最大股東是Cormorant資產管理有限責任公司,其所有權爲19%。Adage Capital Management、L.P. 和千禧管理有限責任公司分別擁有7.6%和5.2%的已發行股份,是第二和第三大股東。

We did some more digging and found that 8 of the top shareholders account for roughly 51% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.

我們做了進一步的挖掘,發現大股東中有8人約佔登記冊的51%,這意味着除了較大的股東外,還有一些較小的股東,從而在一定程度上平衡了彼此的利益。

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.

雖然研究公司的機構所有權數據是有意義的,但研究分析師的情緒以了解風向哪個方向吹來也是有意義的。分析師對該股的報道很少,但報道不多。因此,它還有獲得更多報道的餘地。

Insider Ownership Of Corbus Pharmaceuticals Holdings

Corbus 製藥控股公司的內部所有權

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

公司內部人員的定義可能是主觀的,並且在不同的司法管轄區之間確實有所不同。我們的數據反映了個人內部人士,至少涵蓋了董事會成員。公司管理層對董事會負責,後者應代表股東的利益。值得注意的是,有時高層管理人員自己也是董事會成員。

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

我通常認爲內部所有權是一件好事。但是,在某些情況下,這使其他股東更難追究董事會對決策的責任。

Our data suggests that insiders own under 1% of Corbus Pharmaceuticals Holdings, Inc. in their own names. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. It has a market capitalization of just US$445m, and the board has only US$927k worth of shares in their own names. Many investors in smaller companies prefer to see the board more heavily invested. You can click here to see if those insiders have been buying or selling.

我們的數據顯示,內部人士以自己的名義擁有Corbus Pharmicals Holdings, Inc.不到1%的股份。但是,我們確實注意到,內部人士有可能通過私營公司或其他公司結構獲得間接利益。它的市值僅爲4.45億美元,董事會以自己的名義持有價值92.7萬美元的股票。許多小型公司的投資者更願意看到董事會加大投資力度。你可以點擊這裏查看這些內部人士是否在買入或賣出。

General Public Ownership

一般公有制

The general public-- including retail investors -- own 39% stake in the company, and hence can't easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

包括散戶投資者在內的公衆擁有該公司39%的股份,因此不容忽視。這種所有權規模雖然可觀,但如果決定與其他大股東不同步,可能不足以改變公司的政策。

Private Company Ownership

私人公司所有權

Our data indicates that Private Companies hold 3.3%, of the company's shares. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.

我們的數據顯示,私營公司持有公司3.3%的股份。僅憑這一事實很難得出任何結論,因此值得研究誰擁有這些私營公司。有時,內部人士或其他關聯方通過一家獨立的私人公司對上市公司的股份擁有權益。

Next Steps:

後續步驟:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. For instance, we've identified 5 warning signs for Corbus Pharmaceuticals Holdings (3 don't sit too well with us) that you should be aware of.

我覺得看看究竟誰擁有一家公司非常有趣。但是,要真正獲得見解,我們還需要考慮其他信息。例如,我們已經確定了Corbus Pharmicals Holdings的5個警告信號(其中3個對我們不太滿意),你應該注意這些信號。

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

歸根結底,未來是最重要的。您可以訪問這份關於公司分析師預測的免費報告。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論